By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
The company plans to recruit one million patients from Mexico over three years and then expand to Columbia, Argentina, and Brazil.
The Norwegian microbiome-focused clinical diagnostics company has ceded commercialization rights in certain undisclosed territories to Bio-Rad as part of the deal.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.